The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg. (Q39384899)

11 September 2017

title

The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg. (English)

1 reference

11 September 2017

1 reference

Hans-Christoph Diener

series ordinal

1

object named as

Hans-Christoph Diener

1 reference

11 September 2017

Robert Ryan

2

1 reference

11 September 2017

Wei Sun

series ordinal

3

1 reference

11 September 2017

Jayasena Hettiarachchi

series ordinal

4

1 reference

11 September 2017

publication date

1 February 2004

1 reference

European Journal of Neurology

11 September 2017

published in

1 reference

11 September 2017

volume

11

1 reference

11 September 2017

issue

2

1 reference

11 September 2017

page(s)

125-134

1 reference

Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

Meta-analysis: principles and procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Naratriptan International Recurrence Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT(1B/1D) receptor agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

Health care utilization by migraine patients: a 1998 Medicaid population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

Discrepancies between meta-analyses and subsequent large randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

A comparison of visual analog scale and categorical ratings of headache pain in a randomized controlled clinical trial with migraine patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

Migraine in the United States: epidemiology and patterns of health care use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

Pharmacological treatments for acute migraine: quantitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

Comparison of the Efficacy of Zolmitriptan and Sumatriptan: Issues in Migraine Trial Design

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1351-5101.2003.00730.X

10.1046/J.1351-5101.2003.00730.X

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference